This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.
Dismiss

The Pharmacy Defense Fund supports the FTC's proposed study of generic drug competition

( December 10, 2000, 23:31 GMT | Official Statement) -- MLex Summary: The Pharmacy Defense Fund supports the US Federal Trade Commission's proposed study of generic drug competition saying that innovators of new drug entities are entitled to every minute of patent protection that the laws allow and that regardless of the ongoing destruction of competition, the Pharmacy Defense Fund supports the laws pertaining to the rights and privileges of patents.See the public comment in full below....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents